RP-1 and JP-8 Thermal Stability Experiments

This work experimentally investigates the effect of fuel composition changes on jet and rocket fuel thermal stability. A High Reynolds Number Thermal Stability test device evaluated JP-8 and RP-1 fuels. The experiment consisted of an electrically heated, stainless steel capillary tube with a controlled fuel outlet temperature. An optical pyrometer monitored the increasing external temperature profiles of the capillary tube as deposits build inside during each test. Multiple runs of each fuel composition provided results on measurement repeatability. Testing a t two different facilities provided data on measurement reproducibility. The technique is able to distinguish between thermally stable and unstable compositions of JP-8 and intermediate blends made by combining each composition. The technique is also able to distinguish among standard RP-1 rocket fuels and those having reduced sulfur levels. Carbon burn off analysis of residue in the capillary tubes on the RP-1 fuels correlates with the external temperature results

High Reynolds Number Thermal Stability Experiments

This work represents preliminary thermal stability results for liquid hydrocarbon fuels. High Reynolds Number Thermal Stability experiments with Jet A and RP-1 resulted in a quantitative measurement of the thermal stability. Each fuel flowed through a heated capillary tube that held the outlet temperature at 290 C. An optical pyrometer measured the surface temperature of the tube at 12 locations as a function of time. The High Reynolds Number Thermal Stability number was then determined using standards published by the American Society for Testing and Materials. The results for Jet A showed lower thermal stability than similar tests conducted at another facility. The RP-1 results are the first reported using this technique. Because the temperature rise on the capillary tube during testing for the RP-1 fuels was not significant, a new standard for the testing conditions should be developed for these types of fuels

Adenosine 2A receptor blockade as an immunotherapy for treatment-refractory renal cell cancer

Adenosine mediates immunosuppression within the tumor microenvironment through triggering adenosine 2A receptors (A2AR) on immune cells. To determine whether this pathway could be targeted as an immunotherapy, we performed a phase I clinical trial with a small-molecule A2AR antagonist. We find that this molecule can safely block adenosine signaling in vivo. In a cohort of 68 patients with renal cell cancer (RCC), we also observe clinical responses alone and in combination with an anti-PD-L1 antibody, including subjects who had progressed on PD-1/PD-L1 inhibitors. Durable clinical benefit is associated with increased recruitment of CD8+ T cells into the tumor. Treatment can also broaden the circulating T-cell repertoire. Clinical responses are associated with an adenosine-regulated gene-expression signature in pretreatment tumor biopsies. A2AR signaling, therefore, represents a targetable immune checkpoint distinct from PD-1/PD-L1 that restricts antitumor immunity. SIGNIFICANCE: This first-in-human study of an A2AR antagonist for cancer treatment establishes the safety and feasibility of targeting this pathway by demonstrating antitumor activity with single-agent and anti-PD-L1 combination therapy in patients with refractory RCC. Responding patients possess an adenosine-regulated gene-expression signature in pretreatment tumor biopsies.See related commentary by Sitkovsky, p. 16.This article is highlighted in the In This Issue feature, p. 1